Drug intelligence / Profile preview

mitomycin c + hydroxyurea + vincristine + carmustine

Development stage: Unknown
Lead developer: Kyowa Kirin
Modality: Small Molecules
Administration: Oral, Intravenous, Topical, Ophthalmic

Overview

This is a four-drug combination chemotherapy regimen consisting of mitomycin C (an antineoplastic antibiotic that cross-links DNA), hydroxyurea (an antimetabolite that inhibits ribonucleotide reductase), vincristine (a vinca alkaloid that inhibits microtubule formation), and carmustine (an alkylating agent that cross-links DNA). Each component works through a distinct mechanism to inhibit cancer cell growth and replication. This specific four-drug combination does not appear to be a standardized named regimen in oncology protocols.

Targets

RNR (Ribonucleotide reductase)DNATUBB (Tubulin (alpha and beta subunits))GSR (Glutathione reductase)

Beyond the preview

Go deeper on mitomycin c + hydroxyurea + vincristine + carmustine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mitomycin c + hydroxyurea + vincristine + carmustine.

Explore the full profile